TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Global functional performance
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Symptom relief according to IBS-SSS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in bacterial diversity of supragingival plaque microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficiency of education
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: percent change in non-high-density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With CNS Toxicity of at Least Grade 2 Intensity
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate by CT scan and MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak plasma concentration (Cmax) of total serum iron and serum transferrin-bound iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC) of total serum iron and serum transferrin-bound iron
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: plasma PPi concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of menstrual migraine days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Fugl-Meyer Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Safety and tolerability of BG9924
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Erythrocyte Protoporphyrin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Lowering of Fasting Glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of dose limiting toxicity (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Objective response rate (ORR) by investigator
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental diagnostic value of HyperQ data
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Completing NOTES Repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Irisin Hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: EMG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: VO2 Max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MDI depression score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in levels of gut metabolites in breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change on Test on IPT Concepts
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: change of corneal compensated IOP (IOPcc)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Missed Scheduled Radiotherapy Treatments
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Troponin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fiber recruitment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Bühnenangstfragebogen
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Improvement rate of luminal obstructions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Test score on the Hopkins Verbal Learning Test - Immediate Recall
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Foot Function Index (FFI) for Evaluation of Foot Pain and Disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Area Under the Concentration Versus Time Curve From Time Zero to T (AUC[0-tlast]) of Baseline Adjusted Glucagon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve Extrapolated to Infinity (AUC[0-inf]) of Baseline Adjusted Glucagon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Change From Baseline Concentration (Cmax) of Glucagon
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in right coronary Collateral Flow Index (CFI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of comorbid conditions at baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of Serious Adverse Events and Adverse Events (SAEs and AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with symptoms following VEE vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of subjects with each AE, system organ class of AE, severity, and association with vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical specificity and sensitivity of HIV Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of OTL38 expression in tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: the number and spacing of subsequent pregnancies and births
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: the rates of marriage and cohabitation with the father of the child
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: mothers' employment, career growth, economic self-sufficiency, and welfare dependence
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Effectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CBF values in different brain regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sustained Pain Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With an Injection Site Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC) From Time Zero to Infinity of Galcanezumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Concentration (Cmax) of Galcanezumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Erythrocyte transketolase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in serum lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in rate of resolution of alcohol withdrawal syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delays to treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: O'Leary-Sant Symptom Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Ramsey Sedation Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of samples enrolled per year
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Incidence and progression of caries lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Epithelial cells affinity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 10 repetition sit-to-stand test time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of dose-limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Intravaginal latency time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fewer missed visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fewer unscheduled visits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Fewer emergency visits and hospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Regression of left ventricular mass index (LVMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Myelin Water Fraction (MWF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical accuracy of Moletest application
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Level of non-coding RNAs in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of levetiracetam vs phenytoin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Regional decline in 18F-DTBZ uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: biomarkers related to osteoarthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cmax of Dapagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: AUClast of Dapagliflozin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of skin cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in donor specific antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of treatment related adverse effects of clazakizumab therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Average number of market SNAP transactions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement of Fibrosis Staging (Ishak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of liver fibrosis on MRE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of MELD score or Child Pugh State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of quantitative fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HMGB1 levels in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum and saliva protein markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean MFI-20 score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Mean FSS-7 score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Mental Well-being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Engagement in Meaningful Activity Scale (EMAS)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Perceived Benefits of Horticultural Therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Warm Detection Thresholds and Heat Pain Thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total acquisition time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Methemoglobin Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fall in Patient's Mean Arterial Pressure Greater Than 20%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mother's mental health at 6 months postpartum
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Peak V02 Consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average Time (sec)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best Time (sec)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fatigue Index (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain on the FLACC scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ARFI-SVI measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Normal Sinus Rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: knowledge and practice of regional anesthesia techniques
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: FEV1 at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Disordered eating behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accumulated weight-change in per cent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in renal blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in renal oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Peak exogenous carbohydrate oxidation rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Perceived benefit of intranasal naloxone prescription
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Adverse reactions after vaccination in children
Endpoint domain: Adverse events/effects
Primary endpoint: Continuous Adherence (MEMS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Continuous Adherence (Self-report)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With New Events of Arthralgia
Endpoint domain: Adverse events/effects
Primary endpoint: Patient Pain Perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change From Baseline in Ocular Surface Fluorescein Staining Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in levels of resilience
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Total Walking Area (in Covered Meters)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival of patients based on PVL+ or PVL- strains
Endpoint domain: Mortality/survival
Primary endpoint: Palatability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Biochemical Control Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean N-terminal Pro B-type Natriuretic Peptide (NTproBNP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart Failure Disease Specific Quality of Life (KCCQ-OS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Toilet Tank Assembly Task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Card Sorting Task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Imipenem (IMI) Area Under the Concentration Time Curve From Time 0 to Infinity (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IMI Maximum Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IMI Clearance (CL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mechanical Power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to First On-Study Skeletal Related Event (SRE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in Over-Active Bladder Symptom Score (OABSS) at week 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes in Over-Active Bladder Symptom Score (OABSS) at week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Changes of ECG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes of the Data of Pacemaker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes of UCG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Venous Plasma Heme-oxygenase 1 (HO1) Protein Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Venous Monocyte HO1 Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gastric Emptying Half-time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Possible Side Effects (Drowsiness, Confusion, Nausea)
Endpoint domain: Adverse events/effects
Primary endpoint: Possible Sleep Disturbance
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in EndoPAT Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Airway Submucosal Inflammatory Cells Ratio Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Ischemia-driven Revascularization (IDR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in fat content of milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants Achieving HIV-1 RNA <50 Copies/mL of Plasma at Week 48
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Experiencing ≥1 Adverse Events (AE) up to Week 48
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Who Discontinued Treatment Due to an AE up to Week 48
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients That Experience 1 or More Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Ki (Measure of [18F]FDG Uptake)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite major CVD outcomes
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of PC suspicious lesions detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perineural catheter colonization reduction
Endpoint domain: Adverse events/effects
Primary endpoint: Technical success of thromboaspiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 24-hour cumulative morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Excretion of E2006: urine/feces concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma concentration of E2006/metabolite
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in cerebral blood flow from baseline to 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in brain structure from baseline to 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Participants With Adverse Events (AEs) or Serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients that experience adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients that experience serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of patients with significant changes in ALT levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: changes in target expression in response to corticosteroids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of HIV-seropositive participants with newly diagnosed HIV-infected contacts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: HDRS-21 score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of NETs markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of anti-β2 glycoprotein I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum 25-OH vitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum 1,25 OH vitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intestinal morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Colon Tissue p53 Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in total HIV-1 DNA levels in CD4+ cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Treatment-related Mortality Within 30 Days
Endpoint domain: Mortality/survival
Primary endpoint: Fluctuations in brain activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of patients achieving a plasma testosterone level ≤ 50 ng/dl
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Percentage of patients with complete occlusion of the treated aneurysm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes